An FDA panel is scheduled to review AstraZeneca PLC’s (AZN) drug candidate PT027 on November 8, 2022.PT027 is a potential first-in-class inhaled, fixed-dose combination of Albuterol, the most commonly used asthma treatment, and Budesonide, an inhaled corticosteroid, being developed by AstraZeneca and privately-held Avillion.The proposed indication is for the as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbations in patients with asthma 4 years of age and older.If approved, PT027 could achieve peak sales of $500 million, according to analysts at Jefferies.AZN closed Tuesday’s (Oct 25, 2022) trading at $55.90, up 1.30%.